Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Have people forgotten about OCMillionaires visit? According to him, they had already applied for RAT before his Visit. Check the dates peeps. Gonna be sooner than some of you think
Nobody knows a specific date man. It's not public information. I've emailed the FDA and received that response. Do some real DD and you'll see why so many are willing to wait for the FDA news. It's coming. Be patient. Maybe google search what insider buying means.. google search William P Murphy Jr. Because he just bought 1.2 million shares and he's our chairman of the board here.
Tell that to the OWC* longs lol
My best advice for anyone new checking out this board: go read ALL of hungryhippo's and a couple of the other longs posts. Work harder lolol those guys have really put in some work. I'd love to buy these guys some drinks when it's all said and done. Research every single director and member of us stem cell. The credentials are unheard of in penny world. We have a living legend as our chairman of the board. And the former head of acquisitions from BurgerKing. Legit executives here! And Ms. Comella.... The list goes on
Should've done some DD I guess. Patience man
Bingo! Atleast some of us get it. Do some DD people! There's some good info out there if you dig a little. Like the footnotes of the pacer documents involving buyout offers. It's perfectly reasonable, although speculative, to believe that they already heard back from the FDA and working some deals. Go read hippos and work harder's posts. There's been some great DD on this board, just gotta dig through it all
It was likely submitted before then. That's just when they announced it.
The company announced it
Is the week over? And nobody knows when exactly news will be released.
Not a bad day of consolidation on low volume. Any news will really blow the doors off this thing. FDA Friday after close imo
MODS can we sticky this?
This alone is bigger than most people realize haha WAY bigger imo
Lol relax people. These daily fluctuations are completely irrelevant at this point. Hurry up and wait for news from FDA. Their most recent blog indicates news is coming soon. In the meantime, stop feeding the trolls
They'll know soon enough haha
Nice strength there, but these day to day dips are irrelevant imo. The pending FDA news is what we're all truly waiting on. we'll get it soon and imo it will be very rewarding
Lol so dramatic here. Hurry up and wait is the name of the game. Those with shares upon FDA announcement will be rewarded. Until then, hurry up and wait.
Is it possible the company could be sitting on the news already, waiting to release it? Leverage?
Lol at the pump claims. Yes, a pump n dump scheme 10 years in the making!! Haha ok. Let's spend $120 million on research and development and speak in front of congress to make some money on a pump n dump.
"Why is usrm running"? " what catalysts are causing this?"
I've been seeing a lot of these posts, so I'll sum it up it for you real quick.
The CEO, last week, released a blog highlighting the company's most recent 10k. A very POSITIVE 10k which shows that the company has cleaned up its books. A company that has endured a decade and $120 million worth of research and development has cleaned up its books. Think it's easy to innovate and develop something like usrm is doing? ITS NOT. All odds have been against them and here they are cash positive. Primed for a buyout, but I'll get to that in a second.
The CEO also mentioned in his blog, that usrm has applied to the FDA for RAT designation. Many here, including myself, speculate this news will drop any day now and if you'd been following this company, you too would think this way. We have good reason. RATD, recently renamed, would fast track us to commercialization. The trial results have been positive and the CEO said it himself, he believes they will achieve that designation based on the efficacy of those trials. ANY DAY NOW.
Oh yeah, the new Trump admin and head of the FDA want to deregulate the FDA and streamline the process for approval for these types of companies!
Last Friday, the Chairman of the Board, the legend, William P Murphy Jr. released a form 4 showing he had bought 1.2 million shares for his spouse. Go look it up. Insider buying is VERY GOOD. While you're at it research Mr. Murphy. He's a GENIUS. Look up his last company Cordis (bought out by J & J for $2 billion).
Finally, footnotes from recent pacer filings involved with the Northstar suit mention buyout OFFERS. Yes plural. Dig a little more into Mr. Murphy and his connections. You think he's going to let this company, after spending 120 mil, go for a discount lol. No he's not. Murphy is a winner.
All of this is a small sample of the DD here. Even just going off of financials and technicals, this company is a no brainer.
Scott Gottlieb for FDA is big win for science
http://observer.com/2017/03/fda-nominee-scott-gottleib-rare-disease-drugs/
The dip at the end of the day was just daytraders locking in profits. Same thing was happening during the OWC* assent. Hate to compare the two but the similarities are there. Except usrm possibly has a much bigger catalyst that could send it parabolic (FDA). Just remember, the chairman of the board here is very connected globally and he won't accept failure. The man is a genius, I think many here are overlooking that!
Imagine the demand, being the only FDA approved... BIG $
William P Murphy Jr. do a little DD on him and I think you'll like what you find on our chairman of the board here. Went on the front lines in the Korean War to supply the very blood bags that he helped develop. His company cordis sold for about 2 billion to Johnson & Johnson. You think he's gonna let this fail? I think not imo
Deregulating the FDA :) I expect more smear campaigns as usrm is the first to test these waters
http://www.latimes.com/business/hiltzik/la-fi-hiltzik-gottlieb-fda-20170315-story.html
Yes.
But this new administration will not bow to the media's agenda especially some bogus old news. Like I said stars aligning for usrm. Hope I'm right. Deregulate and make $
Scott Gotlieb :) the stars are aligning my friend
We'll J & J is obviously not happy right now, hence the smear campaign initiated by someone on their payroll. Look back through the DD. This has been proven
Lol just wait for Tomas and crews' response today. SHORT SQUEEZE
How the big players manipulate the stock market
http://seekingalpha.com/instablog/2918951-g-hudson/1026551-how-the-big-players-manipulate-the-stock-market
New FDA Director https://www.nytimes.com/2017/03/10/health/fda-scott-gottlieb.html?_r=0
Stem Cells and the Truth About Medical Innovation
The Wall Street Journal ^ | March 13, 2009 | Scott Gottlieb
Posted on March 14, 2009 at 6:30:40 AM EDT by Scanian
Whatever one thinks of the ethics of using human embryos in medical research, the rhetoric around President Barack Obama's decision to expand federal funding for embryonic stem-cell science reveals a widespread misconception of how medical products are created.
Many of the same political leaders who are the strongest champions for federally funded research seek to impose myriad restrictions, regulations, and economic controls on the private companies that translate public science into practical medical innovations. As a result, while Mr. Obama's stem-cell decision only affects federal funding, and while more funding will mean more research, it's far from certain that this will hasten the realization of new medical products.
The achievements of the National Institutes of Health (NIH) are monumental. But its efforts only translate into practical benefits for patients if its scientific research can be turned into new medicines, something that's not part of the agency's mandate. By its own recent count, the NIH cites only 84 examples over the last 60 years where the agency -- or academic institutions it supports -- discovered, let alone developed, a new drug or biologic.
Making new medicines is the work of a robust private life-science industry. In the case of stem cells, there are more than 150 private companies trying to turn stem cells into new treatments. But almost all of the companies pursuing this sort of chancy science are small biotechnology companies -- the kind that rely on private venture capital in order to fund their high-risk and expensive endeavors.
New FDA Director https://www.nytimes.com/2017/03/10/health/fda-scott-gottlieb.html?_r=0
Stem Cells and the Truth About Medical Innovation
The Wall Street Journal ^ | March 13, 2009 | Scott Gottlieb
Posted on March 14, 2009 at 6:30:40 AM EDT by Scanian
Whatever one thinks of the ethics of using human embryos in medical research, the rhetoric around President Barack Obama's decision to expand federal funding for embryonic stem-cell science reveals a widespread misconception of how medical products are created.
Many of the same political leaders who are the strongest champions for federally funded research seek to impose myriad restrictions, regulations, and economic controls on the private companies that translate public science into practical medical innovations. As a result, while Mr. Obama's stem-cell decision only affects federal funding, and while more funding will mean more research, it's far from certain that this will hasten the realization of new medical products.
The achievements of the National Institutes of Health (NIH) are monumental. But its efforts only translate into practical benefits for patients if its scientific research can be turned into new medicines, something that's not part of the agency's mandate. By its own recent count, the NIH cites only 84 examples over the last 60 years where the agency -- or academic institutions it supports -- discovered, let alone developed, a new drug or biologic.
Making new medicines is the work of a robust private life-science industry. In the case of stem cells, there are more than 150 private companies trying to turn stem cells into new treatments. But almost all of the companies pursuing this sort of chancy science are small biotechnology companies -- the kind that rely on private venture capital in order to fund their high-risk and expensive endeavors.